Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$20.02 +0.7%	$17.64	$13.53 ▼ $35.25	$2.01B	2.07	1.51 million shs	1.36 million shs
SRPT Sarepta Therapeutics	$18.22 +0.1%	$35.34	$16.88 ▼ $154.90	$1.79B	0.45	2.19 million shs	2.48 million shs
TARS Tarsus Pharmaceuticals	$41.08 +1.6%	$43.34	$20.08 ▼ $57.28	$1.73B	0.8	686,567 shs	274,097 shs
TRML Tourmaline Bio	$16.78 +3.6%	$16.81	$11.56 ▼ $29.79	$421.76M	2	256,004 shs	59,085 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	0.00%	+19.17%	+17.76%	+31.11%	-14.74%
SRPT Sarepta Therapeutics	0.00%	+6.46%	-53.55%	-66.53%	-88.10%
TARS Tarsus Pharmaceuticals	0.00%	+1.81%	-6.85%	-12.63%	+42.00%
TRML Tourmaline Bio	0.00%	+1.42%	-11.20%	+30.75%	+30.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	2.4834 of 5 stars	3.5	1.0	0.0	2.5	2.5	0.6
SRPT Sarepta Therapeutics	4.7423 of 5 stars	4.2	2.0	4.2	2.4	1.7	1.9
TARS Tarsus Pharmaceuticals	2.0591 of 5 stars	3.5	0.0	0.0	3.0	1.7	0.6
TRML Tourmaline Bio	2.1135 of 5 stars	3.5	3.0	0.0	0.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.00	Buy	$48.75	143.51% Upside
SRPT Sarepta Therapeutics	2.44	Hold	$60.88	234.20% Upside
TARS Tarsus Pharmaceuticals	3.00	Buy	$66.67	62.28% Upside
TRML Tourmaline Bio	3.00	Buy	$49.33	194.09% Upside

Current Analyst Ratings Breakdown

Latest TRML, TARS, BEAM, and SRPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Sell
6/20/2025	SRPT Sarepta Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$123.00 ➝ $45.00
6/20/2025	SRPT Sarepta Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
6/18/2025	SRPT Sarepta Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$85.00 ➝ $40.00
6/18/2025	SRPT Sarepta Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$24.00
6/17/2025	SRPT Sarepta Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$50.00 ➝ $25.00
6/17/2025	SRPT Sarepta Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$29.00
6/17/2025	SRPT Sarepta Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $30.00
6/17/2025	SRPT Sarepta Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$100.00 ➝ $75.00
6/17/2025	SRPT Sarepta Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$89.00 ➝ $29.00
6/2/2025	TARS Tarsus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$75.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.52M	31.69	N/A	N/A	$8.86 per share	2.26
SRPT Sarepta Therapeutics	$1.90B	0.94	$2.43 per share	7.49	$15.99 per share	1.14
TARS Tarsus Pharmaceuticals	$182.95M	9.43	N/A	N/A	$5.87 per share	7.00
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	$11.71 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$376.74M	-$4.61	N/A	N/A	N/A	-609.24%	-44.24%	-30.97%	8/5/2025 (Estimated)
SRPT Sarepta Therapeutics	$235.24M	-$2.69	N/A	1.66	N/A	-11.12%	-14.88%	-5.12%	8/6/2025 (Estimated)
TARS Tarsus Pharmaceuticals	-$115.55M	-$2.73	N/A	N/A	N/A	-44.91%	-39.72%	-25.74%	8/6/2025 (Estimated)
TRML Tourmaline Bio	-$73.21M	-$3.21	N/A	N/A	N/A	N/A	-26.75%	-26.11%	8/6/2025 (Estimated)

Latest TRML, TARS, BEAM, and SRPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million
5/6/2025	Q1 2025	SRPT Sarepta Therapeutics	$2.20	-$3.42	-$5.62	-$4.60	$685.75 million	$744.86 million
5/2/2025	Q1 2025	TRML Tourmaline Bio	-$0.91	-$0.89	+$0.02	-$0.89	N/A	N/A
5/1/2025	Q1 2025	TARS Tarsus Pharmaceuticals	-$0.69	-$0.64	+$0.05	-$0.64	$72.50 million	$78.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	8.81	8.81
SRPT Sarepta Therapeutics	1.00	4.02	2.46
TARS Tarsus Pharmaceuticals	0.21	5.57	5.54
TRML Tourmaline Bio	N/A	33.87	33.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
SRPT Sarepta Therapeutics	86.68%
TARS Tarsus Pharmaceuticals	90.01%
TRML Tourmaline Bio	91.89%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.50%
SRPT Sarepta Therapeutics	7.70%
TARS Tarsus Pharmaceuticals	8.97%
TRML Tourmaline Bio	13.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	100.56 million	97.04 million	Optionable
SRPT Sarepta Therapeutics	1,372	98.28 million	90.71 million	Optionable
TARS Tarsus Pharmaceuticals	50	42.01 million	38.25 million	Optionable
TRML Tourmaline Bio	44	25.68 million	22.35 million	Optionable

TRML, TARS, BEAM, and SRPT Headlines

Recent News About These Companies

Tourmaline Bio Inc News (TRML) - Investing.com

July 3 at 3:49 PM | investing.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $49.33 Average Price Target from Analysts

June 27, 2025 | americanbankingnews.com

TRML - Tourmaline Bio Inc Dividends - Morningstar

June 26, 2025 | morningstar.comM

TRML - Tourmaline Bio Inc Executives - Morningstar

June 24, 2025 | morningstar.comM

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Rating of "Buy" from Brokerages

June 24, 2025 | marketbeat.com

Cantor Fitzgerald Weighs in on Tourmaline Bio FY2026 Earnings

June 11, 2025 | marketbeat.com

Two Sigma Investments LP Sells 21,904 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML)

June 10, 2025 | marketbeat.com

Tourmaline Bio Elects Directors and Ratifies Auditor

June 6, 2025 | tipranks.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Bought by Bank of America Corp DE

June 6, 2025 | marketbeat.com

H.C. Wainwright maintains $50 target on Tourmaline Bio stock

May 29, 2025 | uk.investing.com

H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results

May 29, 2025 | msn.com

BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML)

May 23, 2025 | msn.com

Tourmaline shares waver as investors mull mid-stage pacibekitug data

May 21, 2025 | thepharmaletter.comT

Tourmaline touts cardiovascular potential of former Pfizer antibody after phase 2 kidney disease win

May 20, 2025 | fiercebiotech.comF

Tourmaline Bio posts mid-stage data for anti-inflammatory agent

May 20, 2025 | msn.com

Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition

May 20, 2025 | seekingalpha.com

Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

May 19, 2025 | globenewswire.com

Tourmaline Bio Reports Q1 2025 Financial Results

May 7, 2025 | tipranks.com

Why Tourmaline Bio, Inc.’s (TRML) Stock Is Down 7.00%

May 3, 2025 | aaii.comA

Tourmaline Bio, Inc.: Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 3, 2025 | finanznachrichten.de

Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 2, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRML, TARS, BEAM, and SRPT Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$20.02 +0.14 (+0.70%)

Closing price 07/3/2025 03:12 PM Eastern

Extended Trading

$20.19 +0.17 (+0.84%)

As of 07/3/2025 04:55 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Sarepta Therapeutics NASDAQ:SRPT

$18.22 +0.03 (+0.14%)

Closing price 07/3/2025 03:55 PM Eastern

Extended Trading

$18.22 0.00 (0.00%)

As of 07/3/2025 04:58 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Tarsus Pharmaceuticals NASDAQ:TARS

$41.08 +0.63 (+1.56%)

As of 07/3/2025 02:30 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Tourmaline Bio NASDAQ:TRML

$16.77 +0.59 (+3.61%)

Closing price 07/3/2025 03:43 PM Eastern

Extended Trading

$16.82 +0.04 (+0.24%)

As of 07/3/2025 04:30 PM Eastern

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time